iCARE4CVD - INDIVIDUALISED CARE FROM EARLY RISK OF CARDIOVASCULAR DISEASE TO ESTABLISHED HEART FAILURE

iCARE4CVD - 从早期心血管疾病风险到确诊心力衰竭的个性化护理

• 批准号: 10104174
• 金额: $ 41.36万
• 依托单位: UNIVERSITY OF GLASGOW
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10104174
• 关键词: iCARE4CVD; INDIVIDUALISED; CARE; EARLY; RISK

The burden of cardiovascular disease (CVD) on society is huge with >85 million people affected in Europe. The overall prevalencecontinues to grow due to unhealthy lifestyles and population aging. Heart failure (HF) is the final common pathway of all CVD and hasa 5 year mortality rate of 20-50% despite significant advances in therapy. iCARE4CVD aims to address this burden by contributing tothree essential steps to improve the current care pathways, covering all stages from early risk to established HF: 1) early diagnosis toidentify patients at risk of CVD and divide them into clinically meaningful subgroups; 2) risk stratification for these subgroups to definethe urgency for intervention; and 3) prediction of treatment response for each subgroup. This will be achieved by the following steps:clinical partners will provide a large set of cohorts including >1,000,000 patients with a wide range of biomarkers (e.g. digital, blood,imaging). Anonymous access to data will be enabled by using a blockchain-supported federated database. Artificial intelligence-basedmodeling also considering patient relevant factors will assess changes in risk and stratify patients according to their individual responsesto therapy. Results will then be prospectively validated in new and ongoing large cohorts and a pilot trial to test the prediction of treatmentresponse by using multiple biomarkers going beyond current risk prediction (such as SCORE) towards individualized therapy. Resultswill be used to provide novel decision tools for each step targeting newly identified subgroups and as a blueprint for innovative futuretrials to individualise prevention and therapy. Patient involvement is key in every part of iCARE4CVD (e.g. patient advisory board) tobuild a motivational framework for self-care by patients. The project brings together an EU-wide consortium with the needed resourcesand expertise from the public and private side to bring iCARE4CVD to success

社会上心血管疾病（CVD）的负担很大，欧洲有8500万人受到影响。由于不健康的生活方式和人口衰老而导致的总体患者增长。心力衰竭（HF）是所有CVD和HASA 5年死亡率20-50％的最终通用途径，尽管治疗取得了重大进展。 ICARE4CVD旨在通过贡献改善当前护理途径的基本步骤来解决这一负担，涵盖从早期风险到既定的HF的所有阶段：1）早期诊断以识别有CVD风险的患者并将其分为具有临床意义的亚组； 2）这些亚组的风险分层确定干预的紧迫性； 3）每个亚组的治疗反应预测。这将通过以下步骤来实现：临床伙伴将提供大量队列，包括> 1,000,000名具有广泛生物标志物的患者（例如数字，血液，成像）。通过使用区块链支持的联合数据库，将启用对数据的匿名访问。基于人工智能的模型还考虑患者相关因素将根据他们的个人反应疗法评估风险变化并对患者进行分层。然后，将在新的和正在进行的大型队列和试点试验中前瞻性验证结果，通过使用多种生物标志物超出当前风险预测（例如得分）对个性化治疗的预测，以测试治疗方案的预测。结果设备可用于为针对新确定的亚组的每个步骤提供新颖的决策工具，并用作创新的未来型预防和治疗的创新未来的蓝图。患者参与是ICARE4CVD（例如患者顾问委员会）的每个部分的关键，为患者的自我保健提供了动机框架。该项目汇集了一个欧盟范围的财团，以及公共和私人方面所需的资源和专业知识，以使ICARE4CVD成功